Potential and limitations of modern combined asthma therapy


Cite item

Full Text

Abstract

Inhalation glucocorticosteroid (ICS) and long-acting beta2-adrenoagonist (LABA) combination currently is the basis of bronchial asthma (BA) treatment in adults with moderate and severe BA, in children with severe BA. The appearance of combination therapies with ICS and LABA components reflects the evolution of views on the asthma treatment. Studies have shown that the use of LABA such as salmeterol and formoterol not only prevent nocturnal asthma symptoms and asthma of physical effort, but also reduce the dose of ICS required achieving adequate control of asthma.

About the authors

N P Knyazheskaya

N P Knyajeskaya

References

  1. Masoli M, Fabian D, Holt S, Beasley R: The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469-78.
  2. Global Initiative for Asthma. Workshop Report, 2006. http://www.ginasthma.com/download.asp?intId=217
  3. Глобальная стратегия лечения и профилактики бронхиальной астмы / Под ред. Чучалина А.Г. М., 2002. С. 1-160.
  4. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroids in asthma patients with symptoms on existing inhaled corticosteroids: Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
  5. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respit Care Med 1996;153:1481-88.
  6. Pauwels RA, Lofdahl CG, Posthma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
  7. Kips JC, O'Connor BJ, Inman MD, et al. A long-termed study of the antiinflammatory effect of low-dosed budesonide plus formoterol versus high-dosed budesonide in asthma. Am Respir Crit Care Med 2000;161:996-1001.
  8. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-97.
  9. Mitchell C, Jenkins C, Scicchitano R, et al. Formoterol (Foradil®) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulmonary Pharmacology & Therapeutics 2003;16:299-306.
  10. Bateman ED, Boushey HA, Bousquet J, et al. Pedersen SE for the GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med 2004;170:836-44.
  11. Lundback B, Ronmark E, Lindberg A, et al. Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006;100(1):2-10.
  12. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticoids increase β2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268:L41-6.
  13. Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med 2001;95(Suppl. B):S12-S16.
  14. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
  15. Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary β2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.
  16. http://www.fda.gov/
  17. Цой А.Н., Архипов В.В., Беда М.В. Клиническая фармакология Серетида и его место в терапии бронхиальной астмы и хроническими обструктивными заболеваниями легких // Качественная клиническая практика. 2002. № 1. С. 90-99.
  18. Dowling RB, Rayner CFJ, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med 1997;155:327-36.
  19. Dowling RB, Jonson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998;11:86-90.
  20. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117:440-46.
  21. Pauwels RA, Sears NR, Cambell M, et al. Formoterol as relie medication in asthma: a world safety and effectiveness trial. Eur Respir J 2003;22:787-94.
  22. Tattersfield AE, Lofdahl C-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised controlled trial. Lancet 2001;357:257-61.
  23. Stallberg B, Olsson P, Jorgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 2003;57(8):656-61.
  24. Aalbers R, Backer V, Kava TTK, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Current Medical Research and Opinion 2004;20(2):225-40.
  25. Ankerst J, Persson G, Weibull E. A high dose of budesonide/formoterol in a single inhaler was well tolerated by asthmatic patients. Eur Respir J 2000;16(Suppl. 31):33s+poster.
  26. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
  27. Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.
  28. Rabe K, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled, double-blind study. Lancet 2006;368:744-53.
  29. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.
  30. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20(9):1403-18.
  31. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, Double-Blind Trial. Chest Feb 2006;129:246-56.
  32. Foster Summary of Product Characteristics. Chiesi Farmaceutici S.p.A.
  33. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2240&mid=1085056570&magid=168&full=1

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies